MXPA02005667A - Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos. - Google Patents
Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos.Info
- Publication number
- MXPA02005667A MXPA02005667A MXPA02005667A MXPA02005667A MXPA02005667A MX PA02005667 A MXPA02005667 A MX PA02005667A MX PA02005667 A MXPA02005667 A MX PA02005667A MX PA02005667 A MXPA02005667 A MX PA02005667A MX PA02005667 A MXPA02005667 A MX PA02005667A
- Authority
- MX
- Mexico
- Prior art keywords
- lycoramine
- galanthamine
- analogs
- modulators
- nicotinic receptors
- Prior art date
Links
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title abstract 4
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 title abstract 4
- GJRMHIXYLGOZSE-JDFRZJQESA-N 1,2-Dihydrogalanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)CC2 GJRMHIXYLGOZSE-JDFRZJQESA-N 0.000 title abstract 2
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 title abstract 2
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 title abstract 2
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 title abstract 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 title abstract 2
- 229960003980 galantamine Drugs 0.000 title abstract 2
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 title abstract 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000000391 smoking effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Los analogos de galantamina y licoramina son utiles en la modulacion de los receptores nicotinicos en humanos y otros animales. La modulacion de estos receptores es util en el tratamiento y/o prevencion de una variedad de condiciones que incluyen el tratamiento de trastornos de la atencion, la provision de ayuda a fumadores y en el tratamiento de la enfermedad de Parkinson.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17003699P | 1999-12-10 | 1999-12-10 | |
| PCT/US2000/042654 WO2001043697A2 (en) | 1999-12-10 | 2000-12-07 | Analogs of galanthamine and lycoramine as modulators of nicotinic receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02005667A true MXPA02005667A (es) | 2004-09-10 |
Family
ID=22618278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02005667A MXPA02005667A (es) | 1999-12-10 | 2000-12-07 | Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6670356B2 (es) |
| EP (2) | EP2311463A1 (es) |
| JP (2) | JP2003516947A (es) |
| AU (1) | AU780012B2 (es) |
| CA (1) | CA2393301A1 (es) |
| MX (1) | MXPA02005667A (es) |
| WO (1) | WO2001043697A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10134038A1 (de) * | 2001-07-12 | 2003-02-06 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit |
| US20030162770A1 (en) | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| WO2005041979A1 (en) * | 2003-10-30 | 2005-05-12 | University Of South Florida | Modulation of microglial by nicotinic medications |
| US20050277626A1 (en) * | 2004-05-27 | 2005-12-15 | Neurocure Ltd. | Methods and compositions for treatment of nicotine dependence and dementias |
| US9132135B2 (en) * | 2004-09-24 | 2015-09-15 | University Of Maryland, Baltimore | Method of treating organophosphorous poisoning |
| EP1791904B1 (en) * | 2004-09-24 | 2014-08-27 | University of Maryland, Baltimore | Method of treating organophosphorous poisoning |
| US20090253654A1 (en) | 2005-09-22 | 2009-10-08 | Galantos Pharma Gmbh | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
| JP5504253B2 (ja) | 2008-04-14 | 2014-05-28 | ニューロダイン ライフ サイエンス インコーポレイテッド | ヒトの脳疾患の治療のためのプロドラッグとしてのガランタミン誘導体 |
| CA2768668A1 (en) * | 2009-07-23 | 2011-01-27 | Shire Llc | Galantamine amino acid and peptide prodrugs and uses thereof |
| CN103812706A (zh) * | 2014-02-26 | 2014-05-21 | 国家电网公司 | 异构厂家数据网网络接口适配方法 |
| EP3122187A4 (en) * | 2014-03-25 | 2017-11-15 | Emicipi LLC | Treatment of rett syndrome |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150354A (en) | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
| AU632458B2 (en) | 1987-05-04 | 1993-01-07 | Bonnie Davis | Compounds for the treatment of alzheimer's disease |
| NZ242744A (en) | 1991-05-14 | 1997-02-24 | Ernir Snorrason | Use of a cholinesterase inhibitor (eg a galanthamine derivative) for treating fatigue |
| DE4301783C1 (de) | 1993-01-23 | 1994-02-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil |
| DE4301782C1 (de) * | 1993-01-23 | 1994-08-25 | Lohmann Therapie Syst Lts | Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit |
| US6323195B1 (en) * | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
| US6316439B1 (en) * | 1993-10-15 | 2001-11-13 | Aventis Pharamaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
| US6323196B1 (en) * | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
-
2000
- 2000-12-07 MX MXPA02005667A patent/MXPA02005667A/es active IP Right Grant
- 2000-12-07 JP JP2001544638A patent/JP2003516947A/ja active Pending
- 2000-12-07 CA CA002393301A patent/CA2393301A1/en not_active Abandoned
- 2000-12-07 US US10/148,253 patent/US6670356B2/en not_active Expired - Lifetime
- 2000-12-07 EP EP10011525A patent/EP2311463A1/en not_active Withdrawn
- 2000-12-07 WO PCT/US2000/042654 patent/WO2001043697A2/en not_active Ceased
- 2000-12-07 AU AU45207/01A patent/AU780012B2/en not_active Ceased
- 2000-12-07 EP EP00992672A patent/EP1237524A4/en not_active Withdrawn
-
2012
- 2012-07-23 JP JP2012162957A patent/JP2012246297A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2311463A1 (en) | 2011-04-20 |
| EP1237524A4 (en) | 2004-06-30 |
| WO2001043697A3 (en) | 2002-01-10 |
| EP1237524A2 (en) | 2002-09-11 |
| JP2012246297A (ja) | 2012-12-13 |
| US20030050281A1 (en) | 2003-03-13 |
| AU4520701A (en) | 2001-06-25 |
| WO2001043697A2 (en) | 2001-06-21 |
| CA2393301A1 (en) | 2001-06-21 |
| AU780012B2 (en) | 2005-02-24 |
| US6670356B2 (en) | 2003-12-30 |
| JP2003516947A (ja) | 2003-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69600596D1 (de) | Zweikammer-schrittmacher-anordnung zur kontinuierlichen regelung des av zeitintervalles mit dem ziel, optimierte stimulierung zur behandlung von kardiomyopathien zu erreichen | |
| WO2003103575A3 (en) | Compounds, compositions, and methods | |
| ATE216879T1 (de) | Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs | |
| AU2002320052A8 (en) | Kcnmas as modifiers of the p53 pathway and methods of use | |
| WO1999045949A3 (en) | Use of follistatin to modulate gdf-8 and bmp-11 | |
| DE69814394D1 (de) | Verwendung von levobupivacain | |
| WO2002084298A3 (en) | Medicaments which are modulators of hm74 and/or hm74a activity | |
| MXPA02005667A (es) | Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos. | |
| WO2001021647A3 (en) | Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases | |
| ATE321548T1 (de) | Verwendung von statin zur behandlung von hauterkrankungen | |
| WO2003087159A8 (en) | Modulators of the notch signalling pathway and uses thereof in medical treatment | |
| DE69825440D1 (de) | VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN | |
| FI973023A0 (fi) | Liikakasvusairauksien yhdistetty terapeuttinen hoito | |
| ATE480297T1 (de) | Elektrisches stimulationssystem zur behandlung von phantomgliederschmerzen | |
| BG105275A (en) | Tan-1057 derivatives | |
| ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| ID23175A (id) | Penggunaan benzopiranol untuk mengobati gangguan syaraf | |
| WO1999016406A3 (en) | Therapeutic method | |
| SE9904863D0 (sv) | New use | |
| AU1521501A (en) | Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders | |
| PL365913A1 (en) | Novel therapeutic use of a thienylcyclohexylamine derivative | |
| MY118760A (en) | Methods for the prevention and treatment of gastrointestinal disorders caused or mediated by algae of cyanobacteria | |
| MXPA02004704A (es) | Analogos de acido hidroxieicosatetraenoico y sus metodos de uso en el tratamiento de trastornos de resequedad del ojo. | |
| UA7192A (uk) | Спосіб масажу біологічно активних точок і інструмент для масажу біологічно активних точок в.в. шушковського | |
| UA33498A (uk) | Спосіб лікування терапевтично резистентних форм шизофренії |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |